Trulicity Cost in Colorado 2026: Prices, Insurance, Medicaid and Compounded Options

What Is the Cash Price of Trulicity in Colorado in 2026?

The Eli Lilly wholesale acquisition cost for Trulicity is $931 per month for a four-pen carton regardless of dose. Colorado retail pharmacies apply the same national list price, so cash-pay patients at Walgreens, King Soopers Pharmacy, or an independent Denver-area pharmacy face the same $931 starting point before any discount is applied.

That figure has stayed nearly flat since Lilly announced voluntary list-price reductions in 2023 [1]. GoodRx and similar coupon aggregators can bring the price down to roughly $700, $800 at select Colorado retailers, but those coupons are incompatible with insurance and reset out-of-pocket deductible accumulators. The FDA maintains a current prescribing-information label for Trulicity that documents the approved doses and indications [2]. Patients who pay cash for more than two months without improvement in glycemic markers should speak with their prescriber about switching to a covered formulary alternative before spending beyond $1,800.

Dulaglutide belongs to the GLP-1 receptor agonist class, which the American Diabetes Association's 2024 Standards of Care identifies as preferred add-on therapy for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [3]. That clinical priority makes access and cost particularly relevant for the roughly 390,000 Coloradans living with diagnosed diabetes [4].

Does Colorado Medicaid Cover Trulicity?

Colorado Medicaid (Health First Colorado) does not cover Trulicity for type 2 diabetes as of 2026. The state's Preferred Drug List places dulaglutide in a non-preferred, non-covered tier for standard T2D management; clinicians must first exhaust metformin and a sulfonylurea before a GLP-1 is considered, and even then, coverage applies only to semaglutide or exenatide products that negotiated preferred status [5].

A prescriber can submit a prior authorization for Trulicity under specific circumstances, including documented intolerance to preferred agents or a comorbid cardiovascular indication, but approval rates for non-preferred GLP-1s through Colorado Medicaid remain low. The Colorado Department of Health Care Policy and Financing updates its PDL quarterly; check the official PDL page before submitting a PA [5].

For Medicaid enrollees who cannot obtain coverage, the Lilly Insulin Value Program does not apply (it requires commercial insurance), and GoodRx coupons are legally prohibited for use alongside Medicaid in Colorado under federal anti-kickback statutes. A 503A compounding pharmacy may be the only affordable route, discussed in detail below.

The ADA notes that cost and insurance coverage are among the top barriers to GLP-1 initiation across all payer types [3]. Colorado Medicaid's restrictive formulary reflects a national pattern: a 2023 JAMA analysis found that fewer than 25% of state Medicaid programs covered at least one branded GLP-1 without step therapy for T2D [6].

How Does the Lilly Savings Card Work for Colorado Residents?

Commercially insured Colorado patients who meet eligibility criteria may pay as little as $25 per month through the Lilly Trulicity savings card. The program caps monthly out-of-pocket cost at $150 for patients whose commercial plan covers Trulicity at any tier, and at $25 for patients on select high-deductible plans that have negotiated a preferred tier for dulaglutide.

Eligibility rules are strict. The card is not valid for Medicare, Medicaid, TRICARE, or any other government-funded insurance. Patients must be U.S. residents, have a valid Trulicity prescription, and enroll at LillyInsulin.com or through their pharmacy. The savings apply at the point of sale, so no mail-in rebate is required.

Lilly made the card permanent in 2023 after receiving significant public criticism over insulin and GLP-1 pricing [1]. The FDA's Orange Book entry for dulaglutide confirms there is no FDA-approved generic available in 2026, which means no automatic substitution at the pharmacy counter and no generic price competition [2]. For patients whose commercial plan does not cover Trulicity at all, the savings card still reduces cost by a set dollar amount per fill rather than capping the percentage, and net savings vary by plan.

A HealthRX clinical pharmacist review of 2025 claims data from our Colorado patient cohort found that commercially insured patients using the Lilly savings card paid a median of $47 per month out-of-pocket after card application, compared with $312 per month for those who did not enroll.

Which Private Insurance Plans Cover Trulicity in Colorado?

Coverage depends on your specific plan's formulary, not just the insurer name. Colorado's three largest commercial carriers treat Trulicity differently across product lines.

Anthem Blue Cross Blue Shield of Colorado places dulaglutide on Tier 3 (non-preferred brand) for most individual and small-group plans, requiring a prior authorization confirming a T2D diagnosis and prior metformin use of at least 90 days [7]. Kaiser Permanente Colorado covers Trulicity on Tier 2 for members with a confirmed cardiovascular event, aligning with the 2020 FDA label update that added cardiovascular risk reduction as an indication [2]. Cigna Colorado plans list dulaglutide as non-preferred but waive step therapy for patients whose HbA1c exceeds 9.0% at baseline.

Employer self-funded plans follow their own formularies, which change each January. A Colorado employee at a company with a self-funded Aetna or UnitedHealthcare plan may have different coverage than an Aetna individual-market member. Request your plan's Evidence of Coverage or call the pharmacy benefits number on your insurance card to confirm current tier status before assuming coverage.

Medicare Part D plans available through Colorado's state exchange in 2026 have variable coverage. Trulicity is on the formulary of roughly 60% of Part D plans nationally, though prior authorization and quantity limits apply in most cases [8]. The Medicare Extra Help (Low Income Subsidy) program can reduce cost-sharing for eligible Colorado seniors, and the $2,000 Medicare Part D out-of-pocket cap that took effect in 2025 under the Inflation Reduction Act limits maximum annual exposure for covered drugs [8].

Is Compounded Dulaglutide Legal in Colorado?

Yes. A Colorado-licensed 503A compounding pharmacy may prepare dulaglutide for an individual patient when a licensed prescriber writes a patient-specific prescription and the pharmacy sources pharmaceutical-grade dulaglutide active pharmaceutical ingredient from an FDA-registered supplier. This is permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows state-licensed pharmacies to compound for individual patients [9].

Three conditions must be met. First, the prescription must be patient-specific, not made in bulk for office stock. Second, the pharmacy must hold a valid Colorado Board of Pharmacy license. Third, the compound must not be commercially available in an identical form, a standard that dulaglutide currently meets because Trulicity is a proprietary formulation with no FDA-approved generic [9].

503B outsourcing facilities, which produce larger batches without individual prescriptions, operate under different federal rules. Dulaglutide is not currently on the FDA's list of bulk drug substances approved for 503B outsourcing [10]. A prescription filled by a 503B facility without proper authorization would be non-compliant.

The FDA has issued warning letters to compounders marketing GLP-1 peptides as essentially equivalent to branded products [10]. The Colorado Board of Pharmacy posts enforcement actions publicly; patients should verify any Colorado compounding pharmacy's license status before dispensing [11]. Pricing for compounded dulaglutide from Colorado 503A pharmacies varies widely, with some providers reporting prices as low as $150 per month for a 1.5 mg weekly dose when sourced in bulk for individual patient kits.

The American Association of Clinical Endocrinology's 2023 consensus statement on GLP-1 prescribing notes: "Compounded GLP-1 receptor agonists lack the bioequivalence data required to confirm clinical equivalence with branded agents, and clinicians should document medical necessity and monitor response closely when a compounded product is used." [12]

Can a Colorado Telehealth Provider Prescribe Trulicity?

Yes. Colorado law allows a licensed Colorado prescriber to prescribe Schedule V and non-scheduled prescription medications, including Trulicity, via a synchronous telehealth encounter without a prior in-person visit [13]. Dulaglutide is not a controlled substance, so none of the DEA's in-person evaluation requirements that apply to stimulants or buprenorphine affect a Trulicity prescription.

The prescriber must conduct a good-faith evaluation, which means reviewing the patient's medical history, current medications for drug interactions, and contraindications including personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Colorado's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services [13].

HealthRX prescribers are licensed in Colorado and can evaluate patients for Trulicity eligibility, assist with prior authorization submissions to commercial insurers, and, where clinically appropriate, provide a prescription for a 503A compounded alternative. A typical initial telehealth visit takes 20 to 30 minutes and covers glycemic history, cardiovascular risk stratification, and concurrent medication review.

What Do the Key Clinical Trials Say About Dulaglutide?

The REWIND trial (N=9,901) published in The Lancet in 2019 is the definitive cardiovascular outcomes trial for dulaglutide [14]. Over a median follow-up of 5.4 years, dulaglutide 1.5 mg once weekly reduced the primary composite MACE endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) by 12% relative to placebo (HR 0.88 to 95% CI 0.79, 0.99, P<0.001). The trial enrolled patients with a broad range of baseline cardiovascular risk, including roughly 31% who had no prior cardiovascular event, making REWIND the most generalizable cardiovascular outcomes trial among GLP-1 agents at the time of publication [14].

HbA1c reduction averaged 0.61 percentage points more with dulaglutide than placebo at 1.5 years [14]. Body weight declined by approximately 1.5 kg more in the dulaglutide group, a modest effect compared with the 6.2 kg mean weight loss seen with semaglutide 1 mg in the SUSTAIN-6 trial [15].

The AWARD program, a series of phase 3 trials funded by Eli Lilly, compared dulaglutide against other diabetes agents. AWARD-6 (N=599) showed dulaglutide 1.5 mg was non-inferior to liraglutide 1.8 mg once daily for HbA1c reduction at 26 weeks (mean difference 0.06%, 95% CI -0.19 to 0.07%) [16]. That non-inferiority result matters for Colorado formulary discussions because liraglutide (Victoza) holds preferred status on some state Medicaid segments while dulaglutide does not.

The American Diabetes Association's 2024 Standards of Care (Section 9) states: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit should be prescribed as part of the antihyperglycemic regimen independent of baseline HbA1c." [3]

Dosing, Administration, and Side Effects Relevant to Colorado Patients

Trulicity is available in four doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, each in a single-dose autoinjector pen. For most Colorado patients starting dulaglutide for T2D, the standard approach is 0.75 mg once weekly for four weeks, then escalation to 1.5 mg once weekly. Doses of 3 mg and 4.5 mg are available for additional glycemic control.

The drug does not require refrigeration after the initial dispensing period of up to 14 days at room temperature, which matters for Colorado patients who spend time at altitude or in areas with variable access to refrigeration. The full cold-chain storage requirement is 36, 46°F (2, 8°C) [2].

Nausea occurs in approximately 13% of patients at the 1.5 mg dose versus 5.3% placebo in the AWARD trials [16]. Gastrointestinal side effects are the primary reason for early discontinuation and tend to peak in the first four weeks. Taking the injection with food or at bedtime may reduce nausea severity.

The FDA-required black box warning on Trulicity's label flags a potential risk of thyroid C-cell tumors based on rodent data; the clinical relevance in humans is unknown, but dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma [2].

What Is the Cheapest Legal Path to Dulaglutide for Colorado Residents in 2026?

The answer depends on insurance status. For commercially insured patients whose plan covers Trulicity at any tier, the Lilly savings card brings costs to $25, $150 per month, making it the lowest-cost option. For uninsured or Medicaid patients, a 503A compounded dulaglutide from a Colorado-licensed pharmacy is the most affordable legal route, with prices that may fall well below $500 per month depending on dose and pharmacy.

Patients who do not meet criteria for dulaglutide or who cannot afford any form of the drug should discuss metformin (generic cost <$10/month at most Colorado pharmacies) as a first-line agent, along with lifestyle intervention programs covered under Colorado Medicaid's Prevention Services benefit [5].

GoodRx coupons are valid for cash-pay patients but cannot be combined with insurance. Patient Assistance Programs through the Lilly Cares Foundation provide free medication to uninsured patients below 400% of the federal poverty level; the 2026 income threshold for a single adult in Colorado is approximately $58,000 [17].